Highlighted Publications

Models to study myelodysplastic syndrome and acute myeloid leukaemia

Current Opinion in Hematology, Nov 28, 2024

We recently wrote a review on the diverse models used to study myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), highlighting their applications and limitations in understanding disease biology and testing therapies. The article focuses on genetically engineered mouse models, human iPSC-derived systems, patient-derived xenografts, and engineered blood stem cells, emphasizing their contributions to advancing translational hematology research.

Mapping the cellular origin and early evolution of leukemia in Down syndrome

Science, Jul 09, 2021

We utilized CRISPR/Cas9-mediated genome editing in human primary disomic and trisomic hematopoietic stem cells to generate an in vivo model of Down syndrome associated leukemia evolution. This humanized model enabled us to study the mechanism of predisposition, preleukemia initiation and leukemic transformation in order to identify potential therapeutic targets of the disease.

Publications Archive

The crossroads of clonal evolution, differentiation hierarchy and ontogeny in leukemia development

Blood Cancer Discovery, Dec 12, 2024

Sturgeon CM, Wagenblast E, Izzo F, Papapetrou EP

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

Nature, Dec 12, 2024

Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, Tomalin LE, Cruz-Rodriguez N, Wang T, Olszewska M, Olivier E, Jaud M, Nadorp B, Kroger B, Hu F, Silverman L, Chung SS, Wagenblast E, Chaligne R, Eisfeld AK, Demircioglu D, Landau DA, Lito P, Papaemmanuil E, DiNardo CD, Hasson D, Konopleva M, Papapetrou EP

LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting

Haematologica, Dec 12, 2024

Quijada-Álamo M, Freed G, Wagenblast E

Models to study myelodysplastic syndrome and acute myeloid leukaemia

Current Opinion in Hematology, Nov 28, 2024

Chao C, Martinez IG, Wagenblast E

Epitope base editing: Non-malignant stem cells are going undercover

Cell Stem Cell, Nov 13, 2023

Saniei S, Wagenblast E

Down syndrome and leukemia: from basic mechanisms to clinical advances

Haematologica, Oct 02, 2023

Baruchel A, Bourquin JP, Crispino J, Cuartero S, Hasle H, Hitzler J, Klusmann JH, Izraeli S, Lane AA, Malinge S, Rabin KR, Roberts I, Ryeom S, Tasian SK, Wagenblast E

A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome

Leukemia, Sep 21, 2022

Boutzen H, Madani Tonekaboni SA, Chan-Seng-Yue M, Murison A, Takayama N, Mbong N, Wagenblast E, Orouji E, Arruda A, Mitchell A, Notta F, Minden MD, Lupien M, Kaufmann KB, Dick JE

Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML

Cell Rep, Mar 08, 2022

Krivdova G, Voisin V, Schoof EM, Marhon SA, Murison A, McLeod JL, Gabra MM, Zeng AGX, Aigner S, Yee BA, Shishkin AA, Van Nostrand EL, Hermans KG, Trotman-Grant AC, Mbong N, Kennedy JA, Gan OI, Wagenblast E, De Carvalho DD, Salmena L, Minden MD, Bader GD, Yeo GW, Dick JE, Lechman ER

TFEB-mediated endolysosomal activity controls human hematopoietic stem cell fate

Cell Stem Cell, Aug 02, 2021

García-Prat L, Kaufmann KB, Schneiter F, Voisin V, Murison A, Chen J, Chan-Seng-Yue M, Gan OI, McLeod JL, Smith SA, Shoong MC, Parris D, Pan K, Zeng AGX, Krivdova G, Gupta K, Takayanagi SI, Wagenblast E, Wang W, Lupien M, Schroeder T, Xie SZ, Dick JE

Mapping the cellular origin and early evolution of leukemia in Down syndrome

Science, Jul 09, 2021

Wagenblast E, Araújo J, Gan OI, Cutting SK, Murison A, Krivdova G, Azkanaz M, McLeod JL, Smith SA, Gratton BA, Marhon SA, Gabra M, Medeiros JJF, Manteghi S, Chen J, Chan-Seng-Yue M, Garcia-Prat L, Salmena L, De Carvalho DD, Abelson S, Abdelhaleem M, Chong K, Roifman M, Shannon P, Wang JCY, Hitzler JK, Chitayat D, Dick JE, Lechman ER